Showing results (21-30 of 112) with videos related to

Sort By:
Pageof 12
Cancers|September 14, 2024
Exploring the Role of CBX3 as a Potential Therapeutic Target in Lung CancerMuhammad Aamir Wahab, Nunzio Del Gaudio, Biagio Gargiulo, et al.
International Journal of Nanomedicine|August 9, 2020
Nano-Encapsulation of Coenzyme Q10 in Secondary and Tertiary Nano-Emulsions for Enhanced Cardioprotection and Hepatoprotection in Human Cardiomyocytes and Hepatocytes During Exposure to Anthracyclines and TrastuzumabVincenzo Quagliariello, Raffaele Vecchione, Alberta De Capua, et al.
Journal of Clinical Medicine|October 16, 2025
The Crucial Role of Tinzaparin in Managing Venous Thromboembolism in the Cancer PopulationAlfredo Mauriello, Adriana Correra, Anna Chiara Maratea, et al.
Journal of Cardiovascular Medicine (Hagerstown, Md.)|May 17, 2016
Pathophysiology of anthracycline cardiotoxicityDonato Mele, Carlo G Tocchetti, Pasquale Pagliaro, et al.
Protein Engineering, Design & Selection : PEDS|January 15, 2014
Effects of a second-generation human anti-ErbB2 ImmunoRNase on trastuzumab-resistant tumors and cardiac cellsChiara D'Avino, Rolando Paciello, Gennaro Riccio, et al.
International Journal of Molecular Sciences|April 26, 2020
Resveratrol in Cancer Patients: From Bench to BedsideMassimiliano Berretta, Alessia Bignucolo, Raffaele Di Francia, et al.
Frontiers in Oncology|June 28, 2021
Polydatin Reduces Cardiotoxicity and Enhances the Anticancer Effects of Sunitinib by Decreasing Pro-Oxidative Stress, Pro-Inflammatory Cytokines, and NLRP3 Inflammasome ExpressionVincenzo Quagliariello, Massimiliano Berretta, Simona Buccolo, et al.
Cancers|March 11, 2023
PCSK9 Inhibitors in Cancer Patients Treated with Immune-Checkpoint Inhibitors to Reduce Cardiovascular Events: New Frontiers in CardioncologyVincenzo Quagliariello, Irma Bisceglia, Massimiliano Berretta, et al.
Cancers|October 29, 2025
Fusobacteriumnucleatum: Pathophysiological and Clinical Involvement in Inflammatory Bowel Diseases, Colorectal Cancer and Cardiovascular DiseasesVincenzo Quagliariello, Pietro Forte, Giuliana Ciappina, et al.
Journal of Personalized Medicine|October 22, 2020
Evidences of CTLA-4 and PD-1 Blocking Agents-Induced Cardiotoxicity in Cellular and Preclinical ModelsVincenzo Quagliariello, Margherita Passariello, Domenica Rea, et al.
Pageof 12